Last reviewed · How we verify

NCT02555059

Special Drug Use Investigation of Ciproxan Injection in Pediatrics

Completed Last updated 28 February 2020
What this trial tests

trial testing Cipro (Ciprofloxacin, BAYQ3939) in Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax in 48 participants. Completed in 13 June 2019.

Timeline
15 July 2016
Primary endpoint
17 December 2018
13 June 2019

Quick facts

Lead sponsorBayer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment48
Start date15 July 2016
Primary completion17 December 2018
Estimated completion13 June 2019
Sites1 location across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Bayer — full company profile →

Who can join

Under 14, any sex, with Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bayer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02555059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing